A Community Gathers for Ostomy Awareness Day Amid Threat to Medical Supplies

United Ostomy Associations of America is organizing National Ostomy Awareness Day events on October 3, 2026, including virtual and in-person 5K fundraisers, while advocating against including ostomy and urological supplies in Medicare competitive bidding. UOAA estimates 725,000 to 1 million Americans live with an ostomy or continent diversion and argues that the recent regulatory ruling could restrict access to prescribed supplies and suppliers. The advocacy effort is supported by device and healthcare-supply companies including Convatec, Coloplast, Hollister, and Byram Healthcare.

Analysis

This is a low-immediacy equity event, but it highlights a potentially material reimbursement-policy risk for ostomy manufacturers and distributors. For Convatec (CTEC), Medicare competitive bidding could reduce realized pricing, increase administrative costs, and shift volume toward winning suppliers; however, the company’s clinical breadth, recurring consumables mix, and patient-specific fitting requirements should make it relatively more resilient than smaller private-label or single-channel vendors. Coloplast (COLO.B) faces similar pricing pressure in its U.S. continence-and-care franchise, though its premium product positioning and international diversification dilute the earnings impact.

The more important second-order issue is channel consolidation. If reimbursement rules favor scale and lowest bid, national DME distributors can gain purchasing leverage over manufacturers, pressuring gross margin even where unit demand remains stable. Conversely, a carve-out based on clinical complexity would preserve product choice and reduce the likelihood of commoditization; that outcome would remove an overhang from CTEC and COLO.B multiples rather than create a major earnings upside.

Over the next 1-3 months, monitor CMS implementation language, Congressional engagement, and distributor contract terms rather than advocacy-event visibility. A negative rulemaking outcome would likely affect FY2027 pricing assumptions before reported volumes, while a delay or exemption could support a modest rerating in the wound/continence-care group. The market should not extrapolate this into a broad medtech demand signal: the addressable patient population is stable and the direct revenue exposure is insufficient to justify a directional trade absent reimbursement detail.

Key Decisions for Investors

• Maintain CTEC as a watch-list long rather than add on this news; initiate only if CMS provides a complexity-based exemption or management quantifies limited U.S. ostomy pricing exposure. Target a 6-12 month holding period, with thesis invalidated by a FY2027 margin guide-down tied to U.S. reimbursement.
• Prefer COLO.B over CTEC on a relative basis if competitive bidding proceeds without an exemption: Coloplast’s broader geographic revenue base should absorb U.S. pricing pressure better. Use the pair long COLO.B / short CTEC only after confirming CTEC’s U.S. ostomy revenue and distributor concentration.
• Set a regulatory alert for final CMS implementation dates and any Congressional carve-out language. A rule delay is more likely to be a sentiment catalyst than an earnings catalyst; avoid buying short-dated options around advocacy milestones.
• Monitor DME distributors and private-label supply vendors for contract-win disclosures; evidence of distributor share gains or manufacturer rebates would be an early warning of gross-margin pressure across CTEC and COLO.B.